Long-acting Cabotegravir/Rilpivirine for Persons who Don’t Fulfill FDA Eligibility Criteria
Dr. Brian Wood reviews recent data and recommendations on use of long-acting, injectable cabotegravir/rilpivirine for individuals with significant challenges to oral ART, including individuals with detectable viral loads.
▶︎
Mini Lecture Series: Long-Acting, Injectable Cabotegravir-Rilpivirine (CAB-RPV)
▶︎
ICAP Grand Rounds — Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls
▶︎
Gabapentin | TRC Healthcare Rumor vs Truth Podcast
▶︎
Perinatal HCV Epidemiology and Reporting in West Virginia by Candice Leferber, Kady Pack & Amna Umer
▶︎
Doctor reveals undisclosed risks of COVID-19 vaccine
▶︎
Recent Trials of Second Line ART Lessons Learned & Applications to Clinical Practice
▶︎
ICU to Home: Managing PN in Complex Adult Patients Short Bowel, Long Journey - Part 2 (ASPEN 2026)
▶︎
CROI 2026 Update: Co-Occurring Condition
▶︎
Why Are Prescription Drugs So Costly in the US? | The Other Drug War (full documentary) | FRONTLINE
▶︎
Long-Acting Injectable PrEP and HIV Treatment Podcast
▶︎
Perinatal HCV Epidemiology and Reporting in West Virginia by Candice Leferber, Kady Pack & Amna Umer
▶︎
Describe the safety and efficacy of newer and investigational treatments for HIV
▶︎
Urinary Tract Infection Pharmacotherapy | TRC Healthcare Medication Talk Podcast
▶︎
Bone Health: Osteoporosis Diagnosis & Management
▶︎
Something is jamming GPS over Europe. Here's what we found
▶︎
Mental Status Examination - Depression - Clinical Skills - Dr Gill
▶︎
PrEP for HIV Prevention: NAT in PrEP
▶︎
The Ebola outbreak the world isn’t paying attention to | The Take
▶︎
IAS-USA Guidelines: Prevention of HIV Infection 2022 Update
▶︎